Literature DB >> 7839447

Central nervous system lymphomas in organ allograft recipients.

I Penn1, G Porat.   

Abstract

Central nervous system (CNS) involvement occurred in 289 of 1332 patients (22%) with posttransplant non-Hodgkins lymphomas. The average time of appearance was 33 months (range 3 weeks to 248.5 months) posttransplantation. Lesions were confined to the CNS in 159 patients (55%), while 130 (45%) had involvement of other organs. Lesions involved the brain in 254 patients (88%), the brain and spinal cord in 5 (2%), the spinal cord in 2 (1%), unspecified locations in the CNS in 13 (4%), the meninges in 8 (3%), and the cerebrospinal fluid (CSF) in 7 (2%). All patients whose only involvement of the CNS was of the meninges or CSF had lymphomas involving multiple organs. Many tumors (48%) appeared within one year after transplantation. Brain lesions were frequently multicentric in distribution. Ninety-one (31%) of the 289 patients had no treatment and died, 70 (77%) of their malignancies and 21 (23%) from other causes. Of 198 patients who received treatment 124 (63%) died of their malignancies; 40 (20%) died of other causes, including 17 patients who had had complete remissions following treatment; 22 (11%) are currently alive and in complete remission; and 12 (6%) are alive and still undergoing therapy. The treatment of choice is local radiotherapy to the brain, which either alone (18 patients) or in combination with other modalities (14 patients) caused 32 of the 39 (82%) complete remissions. Ten of 30 patients with disease localized to the CNS survived more than 5 years, including 6 who survived more than 10 years. CNS lymphomas should be suspected whenever a transplant patient has neurologic symptoms however minor, and prompt work-up is essential to eliminate other possible causes. The dismal prognosis can be improved only by early diagnosis and prompt therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7839447

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  29 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

3.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 4.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

Review 5.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 6.  Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.

Authors:  T Haque; D H Crawford
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  Post Transplant Lymphoproliferative Disorder.

Authors:  Devika Gupta; Satish Mendonca; Sushmita Chakraborty; Tathagata Chatterjee
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-17       Impact factor: 0.900

Review 8.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

9.  EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.

Authors:  J Sanz; M Arango; L Senent; I Jarque; P Montesinos; A Sempere; I Lorenzo; G Martín; F Moscardó; E Mayordomo; M Salavert; C Cañigral; B Boluda; C Salazar; J L López-Hontangas; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

10.  A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.

Authors:  Wendell Lake; Julie E Chang; Tabassum Kennedy; Adam Morgan; Shahriar Salamat; Mustafa K Başkaya
Journal:  Neurosurgery       Date:  2013-06       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.